{"id":"doi:10.1016/j.ajpc.2026.101524","kind":"article","title":"Associations of VICTORION-1 PREVENT eligibility with subclinical cardiovascular and inflammatory damage in a European population-based cohort","authors":["Wang N","Bhatt DL","Xhaard C","Aggarwal R","Bonaca MP","Lesogor A","Dejmek JS","Patel MR","Stroes ESG","Taub PR","Windecker S","Duarte K","Monzo L","Baudry G","Zannad F","Girerd N"],"author_count":16,"year":2026,"published":"2026-04-23","venue":"American journal of preventive cardiology","cited_by":0,"doi":"10.1016/j.ajpc.2026.101524","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1016/j.ajpc.2026.101524","archive_url":"https://space-kitty.com/papers/doi:10.1016/j.ajpc.2026.101524","updated":null,"pmid":"42395072","pmcid":"PMC13325980","openalex_id":null,"pdf_url":"https://europepmc.org/articles/PMC13325980/pdf","abstract":"Background and aims The VICTORION-1 PREVENT (V-1P) trial is evaluating the efficacy of inclisiran versus placebo on cardiovascular events in primary prevention patients at high-risk for ASCVD. We assessed whether V-1P eligibility, based on Pooled Cohort Equations (PCE) and Predicting Risk of Cardiovascular Disease Events (PREVENT) equations, was associated with subclinical cardiovascular and inflammatory abnormalities in a healthy European population. Methods We included individuals from the STANISLAS cohort in France aged 40-79 years, LDL-C 70-189 mg/dL and without ASCVD or liver disease. Participants were categorized as V-1P eligible using 10-year ASCVD risk using PCE and PREVENT. Associations with vascular, echocardiographic, and biomarkers were assessed using age- and sex-adjusted linear regression. Results Among 848 participants (mean age 60 years, 51% female), 16% were eligible per PCE, of which 7% were also eligible with PREVENT. Only one participant was eligible by PREVENT alone. Compared with non-eligible participants, V-1P-eligible individuals, whether by PCE alone or PCE and PREVENT, displayed significant subclinical abnormalities. Compared with V-1P ineligible participants, V-1P eligible participants had increased intima media thickness (+51 µm, p < 0.009 for PCE+PREVENT) and increased mean pulse wave velocity (+0.89 m/s, p < 0.001 for both PCE and PCE+PREVENT) on vascular ultrasound. V-1P eligible participants by PCE+PREVENT also showed signs of subclinical myocardial injury and inflammation, with a 1.3 fold higher troponin ( p = 0.015), 1.6-fold higher interleukin-6 ( p < 0.001) and a 2-fold higher high sensitivity C-reactive protein ( p < 0.001). Conclusions A large proportion of asymptomatic individuals without known cardiovascular disease would be eligible for the V-1P trial based on both PCE and PREVENT equations. V-1P eligible participants had evidence of subclinical cardiovascular and inflammatory abnormalities.","abstract_license":"CC-BY (article license as recorded by Europe PMC; abstract reproduced unmodified apart from markup removal)","license":"CC-BY","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":[],"details":null,"provenance":"europepmc","attribution":"Abstract of \"Associations of VICTORION-1 PREVENT eligibility with subclinical cardiovascular and inflammatory damage in a European population-based cohort\" by Wang N, Bhatt DL, Xhaard C et al., https://doi.org/10.1016/j.ajpc.2026.101524, used under its Creative Commons Attribution license (CC-BY); markup removed, otherwise unmodified.","topics":[{"slug":"cardiovascular-innovation","name":"Cardiovascular Therapeutics","domain_slug":"medicine"}],"cited_in_dossiers":[]}